Value to the Fore: Flexible CRO Solutions Aim to Improve Pipeline Success
White Paper Apr 02, 2012
R&D outsourcing is widely used by pharmaceutical, biotechnology, agricultural and related industries. In order for this to continue, CRO's will need to make higher value contributions i collaborative drug discovery programs.
Trends indicate a return to value, as Contract Research Organizations (CROs) continue to grow their skill sets and ally with the global R&D industry to tap flexible solutions aimed at improving pipeline success. Bruce Molino, Ph.D., Senior Director of Medicinal Chemistry, and Christopher Conway, Senior Director of Business Development, AMRI, analyze the increasing demand for R&D outsourcing and examine how CROs are evolving to better meet industry needs.
Related White Papers
Fully Automated Sensitive Determination of Immunosuppressant Drugs in Whole Blood, using High Quality Internal StandardizationWhite Paper
Measurement of immunosuppressant drugs is essential during organ transplantation. Under-dosing can lead to organ rejection, while over-dosing can cause serious toxicity.READ MORE
8 Reasons why it’s Time to Upgrade to Automated ImagingWhite Paper
Why automated image analysis is rapidly replacing manual microscopy for characterizing particle shape and how combining it with Raman spectroscopy adds chemical identification.READ MORE
7 Key Factors When Considering a Benchtop X-ray DiffractometerWhite Paper
In this white paper, our marketing director of the America’s Kathy Macchiarola outlines the important decisions factors that are key requirements and help you select a benchtop system ideal for your situation and your needs.READ MORE